Janssen
The drugmaker met increased demand following approval of Carvykti in earlier lines of therapy with expanded production at US and European facilities.
Janssen's Rybrevant, Chemo Regimen Nets FDA Approval in EGFR-Mutated NSCLC
The agency reviewed data from the MARIPOSA-2 trial and approved the regimen for patients with common EGFR mutations who are progressing on EGFR inhibitors.
Janssen Pharma to Make CHF 24.6M Milestone Payment to AC Immune Tied to Anti-Tau Alzheimer's Trial
Janssen aims to enroll about 500 participants with presymptomatic Alzheimer's into the Phase IIb ReTain trial testing JNJ-2056.
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Guardant Health Liquid Biopsy CDx Gets Japanese Regulatory Approval for Janssen Lung Cancer Drug
Patients with inoperable or recurrent NSCLC and EGFR exon 20 insertion mutations may be eligible for Janssen Pharmaceutical's amivantamab-vmjw.